Advisory Alpha’s NovoCure NVCR Stock Holding History

Advisory Alpha’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-431	Closed	-$31.3K	–	873
2019 Q3	$31.3K	Buy	+431	New	+$34.5K	0.01%	302

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DCP

Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return

Advisory Alpha's NVCR Position: Q4 2019 in Review

Advisory Alpha sold out of NovoCure (NVCR) in Q4 2019, closing a stake of 431 shares — an estimated $31.3K sold.

Advisory Alpha first reported a position in NVCR in Q3 2019 and held it in 1 quarter. The position peaked at $31.3K in Q3 2019. 262 funds tracked by Wall St. Rank hold NVCR as of Q4 2019.

Advisory Alpha reported no remaining NovoCure position as of Q4 2019 after selling out during the quarter.
Advisory Alpha sold 431 NovoCure shares in Q4 2019, an estimated $31.3K.
Advisory Alpha first reported a position in NovoCure in Q3 2019 and held it in 1 quarter.
Advisory Alpha's NovoCure position peaked at $31.3K in Q3 2019.
262 funds tracked by Wall St. Rank held NovoCure as of Q4 2019.

Based on Advisory Alpha's 13F filing for Q4 2019, filed 14 Feb 2020.